A global player in diagnostic imaging, Guerbet needs to rebuild profitability after years of so-so financial performance (same EBITA as in FY14 for sales up 80%). A tipping point is in sight with the disruptive Gadopiclenol contrast media. Diversification should also pay off as new digital services are unleashed. With the shares out of favour and catalysts building, we see value. A leading player in the field Guerbet is a leading player in the diagnostic imaging field, with deep capabilities ....